Literature DB >> 16319971

The natural history of ductal carcinoma in situ of the breast: a review.

Bircan Erbas1, Elena Provenzano, Jane Armes, Dorota Gertig.   

Abstract

BACKGROUND: Ductal carcinoma in situ represents about 20% of all tumours diagnosed within mammographic screening programs. The natural history of DCIS is poorly understood, as it cannot be observed directly. Estimates of the proportion of DCIS that progress to invasive cancer, as well as factors that may influence progression, are important for clinical management. Here we review various sources of evidence regarding the natural history of DCIS.
METHODS: We identified relevant publications of studies on: follow-up studies of DCIS initially misdiagnosed as benign, studies of recurrence of DCIS as invasive cancer, autopsy studies, studies of risk factors for DCIS, animal studies and studies that used mathematical models to study growth of DCIS and invasive cancer. Data sources included the MEDLINE data base, searches of articles cited in key reviews and editorials.
RESULTS: The most direct evidence regarding the progression of DCIS to invasive cancer comes from studies where DCIS was initially misdiagnosed as benign and treated by biopsy alone. These studies suggest that between 14-53% of DCIS may progress to invasive cancer over a period of 10 or more years. The reported prevalence of undiagnosed DCIS in autopsy studies, of approximately 9%, has been used to suggest a larger reservoir of DCIS may exist in the population. All types of study designs reviewed had limitations that may bias the estimate of progression in either direction.
CONCLUSION: The available evidence suggests not all DCIS will progress to invasive cancer in the medium term but precise estimates of progression are not possible given the limitations of the data. Mathematical modelling of various scenarios of progression and studies of genetic factors involved in progression may shed further light on the natural history of DCIS.

Entities:  

Mesh:

Year:  2005        PMID: 16319971     DOI: 10.1007/s10549-005-9101-z

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  119 in total

Review 1.  Regulation of mammary epithelial cell homeostasis by lncRNAs.

Authors:  Amy N Shore; Jeffrey M Rosen
Journal:  Int J Biochem Cell Biol       Date:  2014-03-26       Impact factor: 5.085

2.  Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.

Authors:  Soley Bayraktar; Nisreen Elsayegh; Angelica M Gutierrez Barrera; Heather Lin; Henry Kuerer; Tunc Tasbas; Kimberly I Muse; Kaylene Ready; Jennifer Litton; Funda Meric-Bernstam; Gabriel N Hortobagyi; Constance T Albarracin; Banu Arun
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

Review 3.  Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis.

Authors:  Iain L O Buxton; Nucharee Yokdang; Robert M Matz
Journal:  Cancer Lett       Date:  2010-05-28       Impact factor: 8.679

4.  Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features.

Authors:  Bibo Shi; Lars J Grimm; Maciej A Mazurowski; Jay A Baker; Jeffrey R Marks; Lorraine M King; Carlo C Maley; E Shelley Hwang; Joseph Y Lo
Journal:  J Am Coll Radiol       Date:  2018-02-02       Impact factor: 5.532

5.  Suspicious breast calcifications undergoing stereotactic biopsy in women ages 70 and over: Breast cancer incidence by BI-RADS descriptors.

Authors:  Lars J Grimm; David Y Johnson; Karen S Johnson; Jay A Baker; Mary Scott Soo; E Shelley Hwang; Sujata V Ghate
Journal:  Eur Radiol       Date:  2016-10-17       Impact factor: 5.315

6.  A 2D mechanistic model of breast ductal carcinoma in situ (DCIS) morphology and progression.

Authors:  Kerri-Ann Norton; Michael Wininger; Gyan Bhanot; Shridar Ganesan; Nicola Barnard; Troy Shinbrot
Journal:  J Theor Biol       Date:  2009-12-16       Impact factor: 2.691

7.  Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds.

Authors:  Naing Lin Shan; Audrey Minden; Philip Furmanski; Min Ji Bak; Li Cai; Roman Wernyj; Davit Sargsyan; David Cheng; Renyi Wu; Hsiao-Chen D Kuo; Shanyi N Li; Mingzhu Fang; Hubert Maehr; Ah-Ng Kong; Nanjoo Suh
Journal:  Cancer Prev Res (Phila)       Date:  2020-05-28

8.  Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS).

Authors:  Frank He; Nora L Springer; Matthew A Whitman; Siddharth P Pathi; Yeonkyung Lee; Sunish Mohanan; Stephen Marcott; Aaron E Chiou; Bryant S Blank; Neil Iyengar; Patrick G Morris; Maxine Jochelson; Clifford A Hudis; Pragya Shah; Jennie A M R Kunitake; Lara A Estroff; Jan Lammerding; Claudia Fischbach
Journal:  Biomaterials       Date:  2019-09-11       Impact factor: 12.479

9.  Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.

Authors:  Yunn-Yi Chen; Sandy DeVries; Joseph Anderson; Juan Lessing; Rebecca Swain; Koei Chin; Veronica Shim; Laura J Esserman; Frederic M Waldman; E Shelley Hwang
Journal:  BMC Cancer       Date:  2009-08-18       Impact factor: 4.430

10.  Magnetic resonance imaging of the natural history of in situ mammary neoplasia in transgenic mice: a pilot study.

Authors:  Sanaz A Jansen; Suzanne D Conzen; Xiaobing Fan; Erica J Markiewicz; Gillian M Newstead; Gregory S Karczmar
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.